Cambium Bio Limited

Quick facts

Phase 3 pipeline

• CAM-101 · Rare genetic disorders / Oncology
  CAM-101 is a gene therapy that delivers a functional copy of the CDKN1C gene to treat Beckwith-Wiedemann syndrome and related imprinting disorders.

Phase 1 pipeline

• CAM-101 10%
• CAM-101 30%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cambium Bio Limited portfolio CI brief
• Cambium Bio Limited pipeline updates RSS